Catalyst Biosciences (CBIO) Stock Price, News & Analysis

Company Overview

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.34 to $7.67
• 52-Week Range: N/A
• Volume: 32,246 shs
• Average Volume: 763,526 shs
• Market Capitalization: $291.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Catalyst Biosciences Stock Analysis - MarketRank™

Catalyst Biosciences scored higher than 6% of companies evaluated by MarketBeat, and ranked 939th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Catalyst Biosciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Catalyst Biosciences are expected to grow in the coming year, from ($0.16) to ($0.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Catalyst Biosciences is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Catalyst Biosciences is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Catalyst Biosciences does not currently pay a dividend.

Dividend Growth

Catalyst Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -0.84

Short Interest

There is no current short interest data available for CBIO.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for CBIO on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Catalyst Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.92% of the stock of Catalyst Biosciences is held by insiders.

Percentage Held by Institutions

Only 5.98% of the stock of Catalyst Biosciences is held by institutions.

CBIO Stock Analysis - Frequently Asked Questions

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced its earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07).

When did Catalyst Biosciences' stock split?

Catalyst Biosciences shares reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Biosciences investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 8/17/2023
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CBIO
• CUSIP: 87611R30
• CIK: 1124105
• Web: www.catalystbiosciences.com
• Phone: (650) 871-0761
• Fax: 336-480-2107
• Employees: 7
• Year Founded: 2003

Profitability

• EPS (Most Recent Fiscal Year): ($1.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,240,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -364.68%
• Return on Assets: -281.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.88
• Quick Ratio: 2.88

Sales & Book Value

• Annual Sales: $790,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.78) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 37,980,000
• Free Float: 36,869,000
• Market Cap: $291.29 million
• Optionable: Optionable
• Beta: 1.05